Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Melanoma × Vaccination × Clear all
NCT01042366 2017-08-16

Dendritic Cells (DC) Vaccine for Metastatic Melanoma

University of Pittsburgh

Phase 2 Terminated
16 enrolled 8 charts
Dermatologic

Melanoma

NCT01216436 2015-05-25

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

Duke University

Phase 1 Terminated
2 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡